Journal of Thoracic Oncology最新文献

筛选
英文 中文
Response to Letter to the Editor 回应致编辑的信
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.08.033
Takashi Kohno PhD, Akifumi Mochizuki MD
{"title":"Response to Letter to the Editor","authors":"Takashi Kohno PhD, Akifumi Mochizuki MD","doi":"10.1016/j.jtho.2024.08.033","DOIUrl":"10.1016/j.jtho.2024.08.033","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 11","pages":"Page e69"},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Toxicity and Mortality After Stereotactic Body Radiotherapy 立体定向体放射治疗后的毒性和死亡率
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.08.010
Shih-Chi Yang MD, Hui-Chin Chang MLS, Shuo-Yan Gau MD, FRSPH
{"title":"Toxicity and Mortality After Stereotactic Body Radiotherapy","authors":"Shih-Chi Yang MD, Hui-Chin Chang MLS, Shuo-Yan Gau MD, FRSPH","doi":"10.1016/j.jtho.2024.08.010","DOIUrl":"10.1016/j.jtho.2024.08.010","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 11","pages":"Pages e70-e71"},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Board of Directors 董事会
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI: 10.1016/S1556-0864(24)02364-5
{"title":"Board of Directors","authors":"","doi":"10.1016/S1556-0864(24)02364-5","DOIUrl":"10.1016/S1556-0864(24)02364-5","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 11","pages":"Page A3"},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Critical Evaluation of Methodologic Approaches in ALK Tyrosine Kinase Inhibitor Research: Addressing Confounding Factors and Statistical Robustness 对 ALK 酪氨酸激酶抑制剂研究方法的严格评估:处理混杂因素和统计稳健性
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.08.020
Wenqin Wang PhD, Xiangzhi Li PhD, Dan Shan MD
{"title":"Critical Evaluation of Methodologic Approaches in ALK Tyrosine Kinase Inhibitor Research: Addressing Confounding Factors and Statistical Robustness","authors":"Wenqin Wang PhD, Xiangzhi Li PhD, Dan Shan MD","doi":"10.1016/j.jtho.2024.08.020","DOIUrl":"10.1016/j.jtho.2024.08.020","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 11","pages":"Pages e64-e65"},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142587292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3 用于检测治疗期间表皮生长因子受体突变阳性晚期非小细胞肺癌进展的循环肿瘤 DNA 纵向分析:来自 FLAURA 和 AURA3 的数据。
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.07.008
Jhanelle E. Gray MD , Aleksandra Markovets PhD , Thanyanan Reungwetwattana MD, MSc , Margarita Majem MD, PhD , Naoyuki Nogami MD, PhD , Nir Peled MD, PhD , Jong-Seok Lee MD , Byoung Chul Cho MD, PhD , Busayamas Chewaskulyong MD , Tom John MD, PhD , Ji-Youn Han MD, PhD , Martin Sebastian MD , Alexander Todd MSc , Yuri Rukazenkov MD, PhD , Carl Barrett PhD , Juliann Chmielecki PhD , Siow Ming Lee PhD, FRCP , Suresh S. Ramalingam MD , Ryan Hartmaier PhD
{"title":"Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3","authors":"Jhanelle E. Gray MD ,&nbsp;Aleksandra Markovets PhD ,&nbsp;Thanyanan Reungwetwattana MD, MSc ,&nbsp;Margarita Majem MD, PhD ,&nbsp;Naoyuki Nogami MD, PhD ,&nbsp;Nir Peled MD, PhD ,&nbsp;Jong-Seok Lee MD ,&nbsp;Byoung Chul Cho MD, PhD ,&nbsp;Busayamas Chewaskulyong MD ,&nbsp;Tom John MD, PhD ,&nbsp;Ji-Youn Han MD, PhD ,&nbsp;Martin Sebastian MD ,&nbsp;Alexander Todd MSc ,&nbsp;Yuri Rukazenkov MD, PhD ,&nbsp;Carl Barrett PhD ,&nbsp;Juliann Chmielecki PhD ,&nbsp;Siow Ming Lee PhD, FRCP ,&nbsp;Suresh S. Ramalingam MD ,&nbsp;Ryan Hartmaier PhD","doi":"10.1016/j.jtho.2024.07.008","DOIUrl":"10.1016/j.jtho.2024.07.008","url":null,"abstract":"<div><h3>Introduction</h3><div>EGFR tyrosine kinase inhibitor (EGFR-TKI)-sensitizing and -resistance mutations may be detected in plasma through circulating tumor DNA (ctDNA). Circulating tumor DNA level changes reflect alterations in tumor burden and could be a dynamic indicator of treatment effect. This analysis aimed to determine whether longitudinal <em>EGFR</em>-mutation ctDNA testing could detect progressive disease (PD) before radiologic detection.</div></div><div><h3>Methods</h3><div>This was a retrospective, exploratory ctDNA analysis in two phase 3 trials (FLAURA, NCT02296125; AURA3, NCT02151981). Patients had treatment-naïve (FLAURA) or EGFR-TKI pre-treated (AURA3) advanced NSCLC with <em>EGFR</em> mutations and on-study PD (RECIST [Response Evaluation Criteria in Solid Tumors]), with a baseline ctDNA result and <em>EGFR</em>-mutation ctDNA monitoring beyond Cycle 3 Day 1. Patients received osimertinib versus comparator EGFR-TKIs (FLAURA) or chemotherapy (AURA3). Outcomes included time from ctDNA PD to RECIST PD and the first subsequent treatment (FLAURA only).</div></div><div><h3>Results</h3><div>Circulating tumor DNA PD preceded or co-occurred with RECIST-defined PD in 93 out of 146 patients (64%) in FLAURA and 82 out of 146 patients (56%) in AURA3. Median time from ctDNA PD to RECIST-defined PD (mo) was 3.4 and 2.6 in the osimertinib and comparator EGFR-TKI arms (FLAURA) and 2.8 and 1.5 in the osimertinib and chemotherapy arms (AURA3). In FLAURA, the median time from ctDNA PD to the first subsequent treatment (mo) was 6.0 and 4.7 in the osimertinib (n = 51) and comparator EGFR-TKI arms (n = 70).</div></div><div><h3>Conclusions</h3><div>Among patients with <em>EGFR</em> mutation-positive advanced NSCLC receiving EGFR-TKI or chemotherapy with ctDNA data and RECIST-defined PD, ctDNA PD preceded/co-occurred with RECIST-defined PD in approximately 60% of cases. Longitudinal ctDNA monitoring may detect PD before radiologic PD.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 11","pages":"Pages 1525-1538"},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141727319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stereotactic Body Radiation Therapy Without Pathologic Diagnosis: A Risky Approach 未经病理诊断的立体定向体放射治疗:有风险的方法
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.08.006
Zhaoning Li MD, Xian Ye MD
{"title":"Stereotactic Body Radiation Therapy Without Pathologic Diagnosis: A Risky Approach","authors":"Zhaoning Li MD,&nbsp;Xian Ye MD","doi":"10.1016/j.jtho.2024.08.006","DOIUrl":"10.1016/j.jtho.2024.08.006","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 11","pages":"Pages e71-e72"},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142587194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An In-Depth Discussion on Dutch Prediction Models for Relevant Acute Toxicity and 90-Day Mortality After Stereotactic Body Radiotherapy for Stage I NSCLC 深入探讨立体定向体外放射治疗 I 期 NSCLC 后相关急性毒性和 90 天死亡率的荷兰预测模型
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.09.1427
Peter S.N. van Rossum MD, PhD, Nienke Wolfhagen MD, Ronald A.M. Damhuis PhD, José S.A. Belderbos MD, PhD
{"title":"An In-Depth Discussion on Dutch Prediction Models for Relevant Acute Toxicity and 90-Day Mortality After Stereotactic Body Radiotherapy for Stage I NSCLC","authors":"Peter S.N. van Rossum MD, PhD,&nbsp;Nienke Wolfhagen MD,&nbsp;Ronald A.M. Damhuis PhD,&nbsp;José S.A. Belderbos MD, PhD","doi":"10.1016/j.jtho.2024.09.1427","DOIUrl":"10.1016/j.jtho.2024.09.1427","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 11","pages":"Pages e74-e77"},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142587197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to “Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813–819]” 对 "简要报告 "的勘误:加拿大癌症试验组 IND.227:pembrolizumab 用于晚期恶性胸膜间皮瘤患者的 II 期随机研究(NCT02784171)。[胸腔肿瘤学杂志》第 18 卷第 6 期:813-819]"。
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.08.017
Maria Carmela Piccirillo MD , Quincy Chu MD , Penelope Bradbury MD , Wei Tu PhD , Courtney H. Coschi MD, PhD , Federica Grosso MD , Marie Florescu MD , Manlio Mencoboni MD , John R. Goffin MD , Maria Pagano MD , Fortunato Ciardiello MD, PhD , Fabiana Letizia Cecere MD , Mark Vincent MD , Roberto Ferrara MD , David E. Dawe MD, MSc , Desiree Hao MD , Christopher W. Lee MD , Alessandro Morabito MD , Cesare Gridelli MD , Luigi Cavanna MD , Scott A. Laurie MD
{"title":"Erratum to “Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813–819]”","authors":"Maria Carmela Piccirillo MD ,&nbsp;Quincy Chu MD ,&nbsp;Penelope Bradbury MD ,&nbsp;Wei Tu PhD ,&nbsp;Courtney H. Coschi MD, PhD ,&nbsp;Federica Grosso MD ,&nbsp;Marie Florescu MD ,&nbsp;Manlio Mencoboni MD ,&nbsp;John R. Goffin MD ,&nbsp;Maria Pagano MD ,&nbsp;Fortunato Ciardiello MD, PhD ,&nbsp;Fabiana Letizia Cecere MD ,&nbsp;Mark Vincent MD ,&nbsp;Roberto Ferrara MD ,&nbsp;David E. Dawe MD, MSc ,&nbsp;Desiree Hao MD ,&nbsp;Christopher W. Lee MD ,&nbsp;Alessandro Morabito MD ,&nbsp;Cesare Gridelli MD ,&nbsp;Luigi Cavanna MD ,&nbsp;Scott A. Laurie MD","doi":"10.1016/j.jtho.2024.08.017","DOIUrl":"10.1016/j.jtho.2024.08.017","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 11","pages":"Pages 1578-1579"},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma IASLC 间皮瘤分期项目:关于即将出版的胸膜间皮瘤 TNM 分类第 9 版中 M 级描述符的建议。
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.08.022
Hedy L. Kindler MD , Adam Rosenthal MS , Dorothy J. Giroux MS , Anna K. Nowak M.B.B.S., PhD , Andrea Billè MD, PhD , Ritu R. Gill M.B.B.S., MPH , Harvey Pass MD , David Rice MD , Robert T. Ripley MD , Andrea Wolf MD, MPH , Kevin G. Blyth MD , Susanna Cedres MD, PhD , Valerie Rusch MD , Members of the IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions
{"title":"The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma","authors":"Hedy L. Kindler MD ,&nbsp;Adam Rosenthal MS ,&nbsp;Dorothy J. Giroux MS ,&nbsp;Anna K. Nowak M.B.B.S., PhD ,&nbsp;Andrea Billè MD, PhD ,&nbsp;Ritu R. Gill M.B.B.S., MPH ,&nbsp;Harvey Pass MD ,&nbsp;David Rice MD ,&nbsp;Robert T. Ripley MD ,&nbsp;Andrea Wolf MD, MPH ,&nbsp;Kevin G. Blyth MD ,&nbsp;Susanna Cedres MD, PhD ,&nbsp;Valerie Rusch MD ,&nbsp;Members of the IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions","doi":"10.1016/j.jtho.2024.08.022","DOIUrl":"10.1016/j.jtho.2024.08.022","url":null,"abstract":"<div><h3>Introduction</h3><div>The International Association for the Study of Lung Cancer developed a global multicenter database to propose evidence-based revisions for the ninth edition of the TNM classification of pleural mesothelioma (PM). This study analyzes the M category to validate eighth edition M category recommendations.</div></div><div><h3>Methods</h3><div>Cases were submitted electronically or by transfer of existing institutional databases for patients with histologically or cytologically confirmed PM. The presence and number of metastases (single versus multiple) in each of eight organ systems were reported for patients with M1 disease at diagnosis. Overall survival (OS) was calculated by the Kaplan-Meier method. Differences in OS were assessed by log-rank test.</div></div><div><h3>Results</h3><div>Of 7338 submitted cases, 3598 were eligible and 3221 had sufficient data for clinical staging; 228 cases (7%) were M1. Median overall estimated survival was inferior for M1 compared with M0 patients: 10.5 months versus 21.5 months, respectively (<em>p</em> &lt; 0.0001); estimated 1-year survival was 46% versus 71%, respectively. OS differences between M categories were preserved within histologic subgroups. Among 158 patients with organ-specific documentation of M1 disease, there was no statistically significant difference in OS between those with intrathoracic versus more distant metastatic disease (14.4 mo versus 10.9 mo, <em>p</em> = 0.64). No significant survival difference was detected between patients with metastatic disease in a single-organ system versus multiple-organ systems (12.6 mo versus 8.8 mo, <em>p</em> = 0.45).</div></div><div><h3>Conclusions</h3><div>This evidence-based analysis of the M category for PM conforms with the eighth edition M descriptors. No changes are proposed in the ninth edition of the mesothelioma M category.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 11","pages":"Pages 1564-1577"},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lung Cancer in Romania 罗马尼亚的肺癌
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI: 10.1016/j.jtho.2024.08.003
Gheorghe-Emilian Olteanu MD, PhD , Alon Vigdorovits MD , Robert Alexandru Barna MD , Laura Mazilu MD, PhD , Veronica Manolache MD , Vladimir Preoteasa MD , Sebastian Curcean MD , Andrei Roman MD, PhD , Natalia Motas MD, PhD , Mircea Dediu MD, PhD , Diana N. Ionescu MD, PhD
{"title":"Lung Cancer in Romania","authors":"Gheorghe-Emilian Olteanu MD, PhD ,&nbsp;Alon Vigdorovits MD ,&nbsp;Robert Alexandru Barna MD ,&nbsp;Laura Mazilu MD, PhD ,&nbsp;Veronica Manolache MD ,&nbsp;Vladimir Preoteasa MD ,&nbsp;Sebastian Curcean MD ,&nbsp;Andrei Roman MD, PhD ,&nbsp;Natalia Motas MD, PhD ,&nbsp;Mircea Dediu MD, PhD ,&nbsp;Diana N. Ionescu MD, PhD","doi":"10.1016/j.jtho.2024.08.003","DOIUrl":"10.1016/j.jtho.2024.08.003","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"19 11","pages":"Pages 1492-1503"},"PeriodicalIF":21.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信